alexa Recombinant Lapidated Subunit Vaccines Induce Robust Immunity Against All Four Serotypes Of Dengue Virus
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Hsin-Wei Chen
National Health Research Institutes, Taiwan
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-057
Our group developed a novel platform to express high levels of recombinant lipoproteins with intrinsic adjuvant properties using an Escherichia coli-based system. These recombinant lipoproteins can activate antigen-presenting cells and induce robust immunity in the absence of exogenous adjuvant formulation. Based on this technology, we developed recombinant lipidated dengue envelope protein domain IIIs as vaccine candidates against dengue virus. In this work, we aim to evaluate the immune responses in mice to the tetravalent formulation. The tetravalent formulation can induce high antibody titers that are stable over a prolonged period of time without exogenous adjuvant formulation. Meanwhile, these antibodies are of high affinity and can neutralize all 4 serotypes of dengue virus. Importantly, the tetravalent formulation elicits multivalent T-cell responses with a wide spectrum of T-cell epitope profiles against all 4 serotypes of dengue virus. These represent important features on dengue vaccine development. Our results reveal that the tetravalent formulation can induce a broad spectrum of immunity in mice, which lays a foundation for further detailed clinical studies.

Hsin-Wei Chen has initiated the development of dengue vaccines project in NHRI. His team has developed a novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Most important, they developed recombinant lipidated dengue subunit vaccine candidates. These candidates independently stimulate long-lasting neutralizing antibodies and reduce the risk of antibody-dependent enhancement. The immune responses induced by the tetravalent formulation in the absence of the exogenous adjuvant are functional in clearing the 4 serotypes of dengue virus in vivo.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version